$XBI $128 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA -6% Initial data from ph 2 booster study in covid variants. source
$CYDY -5% Partner with ARO in Brazil for 2 Covid trials, critically-ill and severe patients. source
Pipeline Updates
$ZYNE +3% Received guidance from FDA for pivotal ph 3 trial of Zygel in Fragile X Syndrome, initiation planned for Q3 '21. source
$CBIO -2% Enrolled first patient in pivotal ph 3 trial (Crimson-01) of MarzAA for Hem A/B. source
$REPL +9% Update to ph 2 RP1 + Opdivo, CR as a PE, and target enrollment 180 patients. source
Financial Updates
$CRVS +6% Sold $10 shares through ATM program to EcoR1 Capital and CEO. source
$AMYT -7% to acquire $CHMA +44% source
$TLSA 0% Agreement with Takanawa to find partner in Japan and Asia for Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. source